Cinqair (reslizumab; Teva) Drug Overview 2018 - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Drug Overview: Cinqair” report has been added to ResearchAndMarkets.com’s offering.

Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.

Key Topics Covered:

List of Figures

Drug assessment summary of Xolair in asthma

Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26

List of Tables

Cinqair drug profile

Cinqair pivotal Phase III data in asthma

Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/fxzcsf/cinqair?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006203/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Asthma Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 02:34 PM/DISC: 05/14/2018 02:34 PM


Update hourly